Nirsevimab and a Community Recall-Based Immunization Strategy for Child Bronchiolitis Prevention - Summary - MDSpire

Nirsevimab and a Community Recall-Based Immunization Strategy for Child Bronchiolitis Prevention

  • By

  • Riccardo Boracchini

  • Benedetta Canova

  • Mirko Cesarini

  • Irene De Marchi

  • Giulia Brigadoi

  • Elisa Barbieri

  • Daniele Donà

  • Carlo Giaquinto

  • Eugenio Baraldi

  • Anna Cantarutti

  • May 19, 2026

  • 0 min

Share

Objective:

To examine the impact of a nirsevimab recall-based immunization strategy on the incidence of clinically diagnosed all-cause bronchiolitis in infants during the 2024-2025 RSV season.

Key Findings:
  • Nirsevimab effectiveness was 48% (95% CI, 29%-62%) in the as-treated analysis.
  • In the per-protocol analysis, nirsevimab effectiveness was 45% (95% CI, 23%-61%).
  • Effectiveness decreased with age: 77% for 2-3 months, 45% for 4-6 months, and 29% for >6 months.
Interpretation:

Nirsevimab was associated with a significant reduction in the risk of clinically diagnosed all-cause bronchiolitis, particularly in younger infants.

Limitations:
  • Small sample size.
  • Potential for residual regional confounding.
Conclusion:

The study supports the effectiveness of recall-based nirsevimab immunization strategies in community pediatric practice, especially for older, previously unexposed infants.

Original Source(s)

Nirsevimab and a Community Recall-Based Immunization Strategy for Child Bronchiolitis Prevention

  • by Riccardo Boracchini, Benedetta Canova, Mirko Cesarini, Irene De Marchi, Giulia Brigadoi, Elisa Barbieri, Daniele Donà, Carlo Giaquinto, Eugenio Baraldi, Anna Cantarutti

  • May 19, 2026

Related Content

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.